İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2015

Challenges and differences in external radiation therapy for retinoblastoma from standard techniques to new developments

Dergi

Tumori Journal

ISSN 0300-8916

ISSN kaydı başka bir dergiye işaret ediyor; ad YÖKSİS kaydından.

YÖKSİS OpenAlex Açık erişim · diamond SJR Q2 JCR Q4 Atıf 68 Yüzdelik 87.3% FWCI 2.16
Yıl
2015
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • YÖKSİS dergi adı Tumori Journal
  • Katalog eşleşmesi (ISSN) Tumori
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

OpenAlex · Türkçe

Retinoblastoma (RB) is the most common childhood malignant intraocular tumor. Although enucleation and external beam radiotherapy have been historically used, today the most commonly used eye-sparing approach is chemotherapy. Chemotherapy can be used in both intraocular and extraocular RB cases. Chemotherapeutic agents may be applied in different ways, including systemic, subconjunctival, intra-arterial and intravitreal routes. The main purposes of application of systemic therapy are to reduce the tumor size for local treatment (chemoreduction), or to reduce the risk of metastasis after enucleation surgery (adjuvant therapy). Intra-arterial chemotherapy with the current name "super-selective intra-arterial infusion therapy" could be applied as primary therapy in tumors confined to the retina or as a secondary method in tumor recurrence. The most important advantage of intra-arterial therapy is the prevention of systemic chemotherapy complications. Intravitreal chemotherapy is administered in the presence of persistent or recurrent vitreous seeding. The term "extraocular RB" includes orbital invasion and metastatic disease. Current treatment for orbital invasion is neoadjuvant chemotherapy followed by surgical enucleation and adjuvant chemotherapy and radiotherapy after surgery. In metastatic disease, regional lymph node involvement, distant metastases, and/or central nervous system (CNS) involvement may occur. Among them, CNS involvement has the worst prognosis, remaining at almost 100% mortality. In metastatic disease, high-dose salvage chemotherapy and autologous hematopoietic stem cell rescue therapy are the possible treatment options; radiotherapy could also be added to the protocol according to the side of involvement.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

68 atıf

OpenAlex cited_by_count (önbellek / veritabanı)

Yazarlar

  1. ayse hicsonmez
  2. güney yalcın
  3. NURDAN TAÇYILDIZ ANKARA ÜNİVERSİTESİ
  4. yavuz gulsan
  5. EMEL ÜNAL
  6. dizman ahmet
  7. dirican betul
  8. yavuz arslan
  9. atakul taner
  10. halil uysal
  11. gunduz kaan
  12. HANDAN UĞUR DİNÇASLAN
  13. andreu meltem